Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Yong, Bicheng ^a   Tan, Pingxian ^a   Yin, Junqiang ^a   Zou, Changye ^a   Xie, Xianbiao ^a   Wang, Jin ^a   Huang, Gang ^a   Wang, Qianyong ^a   Shen, Jingnan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Osteosarcoma; Suboptimal chemotherapy; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MESNA; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GROWTH ACCELERATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84866147628     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-191     Document Type: Article

References (29)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790. 10.1200/JCO.20.3.776, 11821461.
2. Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011, 2011:548151. 3061299, 21437228.
3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6:1075-1085. 10.1586/14737140.6.7.1075, 16831079.
4. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, Graf N, Heise U, Jurgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998, 9:893-899. 10.1023/A:1008391103132, 9789613.
5. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C, . Italian Sarcoma Group/Scandinavian Sarcoma Group High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002, 14:198-206. Italian Sarcoma Group/Scandinavian Sarcoma Group.
6. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G, . Italian and Scandinavian Sarcoma Groups Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005, 23:8845-8852. 10.1200/JCO.2004.00.5785, 16246977, Italian and Scandinavian Sarcoma Groups.
7. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, . Children's Oncology Group Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol 2008, 26:633-638. 10.1200/JCO.2008.14.0095, 18235123, Children's Oncology Group.
8. Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, Shen Z, Yao Y, Dong Y. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol 2011, 7:270-275. 10.1111/j.1743-7563.2011.01406.x, 21884438.
9. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980, (153):106-120.
10. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997, 79:411-415. 10.1002/(SICI)1097-0142(19970115)79:2<411::AID-CNCR26>3.0.CO;2-2, 9010116.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
12. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ. Cancer Management: A Multidisciplinary Approach 2009, Manhaset, NY: CMP Medica, 11.
13. Zhang Q, Xu WP, Guo W. The current status of the treatment for osteosarcoma in China. Chin J Bone Tumor Bone Dis 2009, 8:129-132.
14. Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 2011, 82:211-216. 10.3109/17453674.2011.566141, 3235293, 21434784.
15. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45:992-1005. 10.1016/j.ejca.2008.11.042, 19231160.
16. Bielack S, Jurgens H, Jundt G, Kevric M, Kuhne T, Reichardt P, Zoubek A, Werner M, Winkelmann W, Kotz R. Osteosarcoma: the COSS experience. Cancer Treat Res 2009, 152:289-308. 10.1007/978-1-4419-0284-9_15, 20213397.
17. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006, 32:423-436. 10.1016/j.ctrv.2006.05.005, 16860938.
18. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007, 19:341-346. 10.1097/CCO.0b013e328122d73f, 17545797.
19. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49:1221-1230. 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E, 6174200.
20. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 2005, 41:2836-2845. 10.1016/j.ejca.2005.08.026, 16298125.
21. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):137-139.
22. Jeon DG, Song WS. How can survival be improved in localized osteosarcoma?. Expert Rev Anticancer Ther 2010, 10:1313-1325. 10.1586/era.10.79, 20735316.
23. Bacci G, Ferrari S, Longhi A, Forni C, Ruggieri P, Briccoli A, De Paolis M, Setola E. Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol 2003, 21:4662-4663. 10.1200/JCO.2003.99.157, 14673070.
24. Bajpai J, Puri A, Shah K, Susan D, Jambhekar N, Rekhi B, Desai S, Gulia A, Gupta S. Chemotherapy compliance in patients with osteosarcoma. Pediatr Blood Cancer 2012,
25. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994, 12:2699-2705.
26. Lewis C, Linet MS, Abeloff MD. Compliance with cancer therapy by patients and physicians. Am J Med 1977, 101:14-18.
27. Balasubramanian SP, Murrow S, Holt S, Manifold IH, Reed MW. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003, 12:136-141. 10.1016/S0960-9776(02)00263-1, 14659343.
28. Yu X, Li C, Shi Y, Yu M. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy 2010, 97:8-15. 10.1016/j.healthpol.2010.02.010, 20307912.
29. Song P, Wu Q, Huang Y. Multidisciplinary team and team oncology medicine research and development in China. Biosci Trends 2010, 4:151-160.